Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR202, an early-stage camsirubicin analog for various cancers.
Company Details
- Employees
- 19
- Founded
- -
- Address
- 1000 Skokie Blvd, Wilmette,illinois 60091,united States
- Phone
- (847) 388-0349
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- monopartx.com
- Keywords
- Specialist jobs.
- HQ
- Wilmette, Illinois
Monopar Therapeutics Inc. Questions
Monopar Therapeutics Inc.'s helpline number is (847) 388-0349
Monopar Therapeutics Inc.'s website is monopartx.com
Monopar Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/monopar-therapeutics-inc
Monopar Therapeutics Inc. has
19 employees.
View email and phone details for 19
employees at Monopar Therapeutics Inc..
Monopar Therapeutics Inc.'s industry is
Biotechnology Research
Monopar Therapeutics Inc.'s top competitors are
Candid Therapeutics,
Dimension Bio,
Daigger Scientific,
Xentria, Inc.,
Centessa Pharmaceuticals,
World Bioproducts Llc,
Summit Therapeutics, Inc.,
Emalex Biosciences,
Prenosis,
Stoelting Co..
Monopar Therapeutics Inc.'s support email address is info@monopartherapeutics.com
Monopar Therapeutics Inc.'s categories are Biotechnology Research
Monopar Therapeutics Inc.'s founding year is 2015
